Time course of the changes in antipsychotic-induced hyperprolactinemia following the switch to aripiprazole

[1]  Ming-Chyi Huang,et al.  Aripiprazole resolves symptomatic hyperprolactinemia in a male schizophrenic patient , 2008, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[2]  R. Williamson,et al.  Change in sexual dysfunction with aripiprazole: a switching or add-on study , 2008, Journal of psychopharmacology.

[3]  M. Byerly,et al.  Clinical Implications of Antipsychotic-Induced Hyperprolactinemia in Patients With Schizophrenia Spectrum or Bipolar Spectrum Disorders: Recent Developments and Current Perspectives , 2007, Journal of clinical psychopharmacology.

[4]  M. Shaw,et al.  Prevalence of hyperprolactinaemia in a naturalistic cohort of schizophrenia and bipolar outpatients during treatment with typical and atypical antipsychotics , 2007, Journal of psychopharmacology.

[5]  R. Conley,et al.  Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial. , 2007, The American journal of psychiatry.

[6]  J. Wolf,et al.  Hyperprolactinemia and amenorrhea associated with olanzapine normalized after addition of aripiprazole , 2007, Journal of clinical pharmacy and therapeutics.

[7]  G. Gründer,et al.  Amisulpride-induced hyperprolactinaemia is not reversed by addition of aripiprazole. , 2007, The international journal of neuropsychopharmacology.

[8]  P. Fletcher,et al.  Dissociation between In Vivo Occupancy and Functional Antagonism of Dopamine D2 Receptors: Comparing Aripiprazole to Other Antipsychotics in Animal Models , 2006, Neuropsychopharmacology.

[9]  Shih-ku Lin,et al.  Reversal of antipsychotic-induced hyperprolactinemia, weight gain, and dyslipidemia by aripiprazole: A case report. , 2006, The Journal of clinical psychiatry.

[10]  P. Weiden.  Switching antipsychotics: an updated review with a focus on quetiapine , 2006, Journal of psychopharmacology.

[11]  M. Lambert,et al.  Aripiprazole: a new atypical antipsychotic with a different pharmacological mechanism , 2004, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[12]  C. Altar,et al.  Mechanism of Action of Aripiprazole Predicts Clinical Efficacy and a Favourable Side-Effect Profile , 2004, Journal of psychopharmacology.

[13]  S. Kapur,et al.  Half a century of antipsychotics and still a central role for dopamine D2 receptors , 2003, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[14]  R. Mailman,et al.  Aripiprazole, A Novel Atypical Antipsychotic Drug with a Unique and Robust Pharmacology , 2003, Neuropsychopharmacology.

[15]  A. Wieck,et al.  Antipsychotic-induced hyperprolactinaemia in women: pathophysiology, severity and consequences , 2003, British Journal of Psychiatry.

[16]  D. Jody,et al.  Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study , 2003, Psychopharmacology.

[17]  J. Kane,et al.  Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. , 2002, The Journal of clinical psychiatry.

[18]  S. Kapur,et al.  The Differential Effects of Atypical Antipsychotics on Prolactin Elevation Are Explained by Their Differential Blood-Brain Disposition: A Pharmacological Analysis in Rats , 2002, Journal of Pharmacology and Experimental Therapeutics.

[19]  T. Kikuchi,et al.  The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor , 2001, European Neuropsychopharmacology.

[20]  Gary Remington,et al.  Dopamine D2 receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient , 2001, Biological Psychiatry.

[21]  N. N. Available.  World medical association declaration of Helsinki , 2000, Chinese Journal of Integrative Medicine.

[22]  Wolzt,et al.  World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. , 2003, The Journal of the American College of Dentists.

[23]  H. Meltzer,et al.  Effects of antipsychotic drugs on extracellular dopamine levels in rat medial prefrontal cortex and nucleus accumbens. , 1999, The Journal of pharmacology and experimental therapeutics.

[24]  X. Páez,et al.  Effects of the antipsychotic drug sulpiride on reproductive hormones in healthy premenopausal women: relationship with body weight regulation. , 1997, Pharmacopsychiatry.

[25]  M. Mauri,et al.  A Risk-Benefit Assessment of Sulpiride in the Treatment of Schizophrenia , 1996, Drug safety.

[26]  J. Peedicayil,et al.  A STUDY OF SERUM PROLACTIN LEVELS IN SCHIZOPHRENIA: COMPARISON OF MALES AND FEMALES , 1992, Clinical and experimental pharmacology & physiology.

[27]  U. Ahlfors,et al.  The UKU side effect rating scale: A new comprehensive rating scale for psychotropic drugs and a cross‐sectional study of side effects in neuroleptic‐treated patients , 1987, Acta psychiatrica Scandinavica. Supplementum.

[28]  W. Brown,et al.  Tolerance to the prolactin-elevating effect of neuroleptics , 1981, Psychiatry Research.

[29]  S. Lal,et al.  EFFECT OF ACUTE AND CHRONIC NEUROLEPTIC THERAPY ON SERUM PROLACTIN LEVELS IN MEN AND WOMEN OF DIFFERENT AGE GROUPS , 1976, Clinical endocrinology.

[30]  H. Meltzer,et al.  The effect of neuroleptics on serum prolactin in schizophrenic patients. , 1976, Archives of general psychiatry.

[31]  R. Bridler.  [Aripiprazole in the treatment of schizophrenia]. , 2005, Praxis.

[32]  G. Gabbard,et al.  Reversal of Symptomatic Hyperprolactinemia by Aripiprazole , 2005 .

[33]  A. Wieck,et al.  Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management. , 2004, Drugs.

[34]  M. F. Denisov.  Re: Prolactin levels and adverse events in patients treated with risperidone. , 2002, Journal of clinical psychopharmacology.

[35]  S. Kay,et al.  The positive and negative syndrome scale (PANSS) for schizophrenia. , 1987, Schizophrenia bulletin.

[36]  A. Frantz,et al.  Prolactin responses to neuroleptics in normal and schizophrenic subjects. , 1978, Archives of general psychiatry.